Effectiveness and cost-effectiveness of pembrolizumab in persistent, recurrent, or metastatic cervical cancer with PD-L1 CPS 1-10: secondary analysis of KEYNOTE-826 using innovative KMSubtraction.
来源：PubMed发布日期：2026-06-16作者：Zhou J, Cai J, Zhang L, Zhu Y, Lin L0 次点击